Safranal

Other Names

(2,6,6-Trimethylcyclohexa-1,3-dienyl)methanal1,1,3-Trimethyl-2-formylcyclohexa-2,4-diene1,3-Cyclohexadiene-1-carboxaldehyde, 2,6,6-trimethyl-2,2,6-Trimethyl-4,6-cyclohexadien-1-aldehyde2,3-Dihydro-2,2,6-trimethylbenzaldehyde2,6,6-Trimethyl-1,3-cyclohexadien-1-carbaldehyd2,6,6-Trimethyl-1,3-cyclohexadienal2,6,6-Trimethyl-1,3-cyclohexadiene-1-carbaldehyde2,6,6-Triméthyl-1,3-cyclohexadiène-1-carbaldéhyde2,6,6-trimethyl-1-cyclohexa-1,3-dienecarboxaldehyde2,6,6-trimethyl-3-cyclohexadiene-1-carboxaldehyde2,6,6-Trimethylcyclohexa-1,3-dien-1-carboxaldehyde2,6,6-Trimethylcyclohexa-1,3-diene-1-carbaldehyde2,6,6-Trimethylcyclohexa-1,3-dienecarbaldehyde2,6,6-Trimethylcyclohexa-1,3-dienylmethanal3,4-Didehydro-7-apo-beta-caroten-7-alDehydro-beta-cyclocitralSafralan

Synopsis

Safranal: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Nomenclature and Molecular Identity

Safranal is a monoterpene aldehyde and the major volatile component of saffron, responsible for the spice's unique odor. Its systematic IUPAC name is 2,6,6-trimethylcyclohexa-1,3-diene-1-carbaldehyde, and it is also commonly designated by the name 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxaldehyde. Its molecular formula is C₁₀H₁₄O. As a monoterpene, safranal belongs to the broader class of terpenoids and carries a single aldehyde functional group attached to a six-membered cyclohexadiene ring bearing three methyl substituents.

1.2 Natural Source and Botanical Origin

Safranal is an organic compound isolated from saffron, the spice consisting of the stigmas of crocus flowers (Crocus sativus). Crocus sativus belongs to the family Iridaceae. There are more than 150 different compounds in saffron comprising carbohydrates, polypeptides, lipids, water, minerals and vitamins. Among these, saffron has four main bioactive components: crocin (C₄₄H₆₄O₂₄), crocetin (C₂₀H₂₄O₄), picrocrocin (C₁₆H₂₆O₇), and safranal (C₁₀H₁₄O).

Picrocrocin is a truncated version of the carotenoid zeaxanthin produced via oxidative cleavage, and is the glycoside of the terpene aldehyde safranal. When saffron is dried after harvest, heat combined with enzymatic action splits picrocrocin to yield D-glucose and a free safranal molecule. Thus, safranal is not simply extracted directly from the plant as a preformed compound; rather, it is generated through both enzymatic and thermal degradation of its glucoside precursor picrocrocin during the post-harvest drying process.

1.3 Abundance and Concentration in Saffron

Safranal constitutes 30–70% of the volatile compounds of saffron and 0.001–0.006% of saffron dry matter. It is responsible for the odor of saffron. The amount of safranal in Iranian saffron is 0.06–0.29 mg/g. Safranal, a volatile oil, gives saffron much of its distinctive aroma. Safranal is less bitter than picrocrocin and may comprise up to 70% of dry saffron's volatile fraction in some samples. The International Organization for Standardization (ISO) includes safranal content (measured by its UV absorbance at 330 nm) as one of the three key quality parameters for commercial saffron grading.

1.4 Physical and Chemical Properties

Chemically, safranal is a monoterpene aldehyde possessing a sweet fragrance. As a volatile compound, it is lipophilic in character. Safranal, a lipophilic volatile compound, crosses the blood–brain barrier more readily than the more hydrophilic saffron constituents such as crocins. This lipophilicity is an important pharmacokinetic consideration. Dry saffron is highly sensitive to fluctuating pH levels, and rapidly breaks down chemically in the presence of light and oxidizing agents; it must therefore be stored in air-tight containers to minimize contact with atmospheric oxygen.

1.5 Common Forms and Preparations

Safranal is encountered in several distinct forms in research and commercial contexts:

Saffron stigma preparations: Dried stigmas of Crocus sativus contain safranal as the dominant volatile component and are the traditional whole-plant form. Aqueous or hydroalcoholic infusions of stigmas liberate safranal through the hydrolysis of picrocrocin.
Standardized saffron extracts: Commercial extracts such as Affron® and Satiereal® are standardized to specified levels of saffron's active constituents and used in clinical research. A novel saffron extract termed Affron® at a low dose of 28 mg/day has been used in clinical trials assessing mood, stress, anxiety, and sleep quality.
Isolated pure safranal: Safranal's natural concentration in saffron stigmas is relatively low, making it difficult to isolate sufficient amounts of the compound directly from plant material for experimental purposes. For this reason, pure safranal can be prepared from its direct precursor 4-hydroxysafranal, obtained in turn from picrocrocin.
Essential oil preparations: Safranal constitutes the primary volatile constituent of the essential oil fraction of saffron and can be captured via steam distillation or supercritical fluid extraction.
Nanotechnology-based formulations: Safranal's poor oral bioavailability is a major limitation; approaches based on chemical modifications or innovative formulations, such as nanoparticles or intranasal administration, could improve its stability and absorption.

2. Traditional and Historical Use

2.1 Ancient Origins and Early Civilizations

The history of saffron—and by extension, the aromatic compounds it contains—extends deep into antiquity. Documentation of the use of saffron over a span of 3,500 years has been uncovered. Saffron-based pigments have been found in 50,000-year-old depictions of prehistoric places in northwest Iran. The Sumerians later used wild-growing saffron in their remedies and magical potions, and it was also known in ancient Egypt, as indicated by a 2000 BC papyrus.

Several data in old pharmaceutical books, like Avicenna's Book of Canon, the Persian Aghili, and Galenus, dealt with its medicinal use. Saffron has been used since the Stone Age; traces of saffron pigment were proved by modern methods in a prehistoric cave in Iraq and in wall paintings in Santorini, Greece. These fresco paintings in Santorini are 3,000–5,000 years old and show saffron scenes.

2.2 Ancient Persian Use

Persian saffron was cultivated at Derbena and Isfahan in the 10th century BC, where saffron threads have been found interwoven into ancient Persian royal carpets and funeral shrouds. Saffron was used by ancient Persian worshippers as a ritual offering to their deities, and as a brilliant yellow dye, perfume, and a medicine. Saffron threads would be scattered across beds and mixed into hot teas as a curative for bouts of melancholy. This use of saffron-infused hot tea as a remedy for depression or melancholy is particularly relevant in the context of safranal's modern scientific investigation for its antidepressant and anxiolytic properties.

During his Asian campaigns, Alexander the Great used Persian saffron in his infusions, rice, and baths as a curative for battle wounds. Alexander's troops imitated the practice from the Persians and brought saffron-bathing to Greece.

2.3 Greek and Roman Use

In Ancient Greece, saffron was known as a valuable and medicinal spice. In ancient Greece, saffron was associated with healing and was used for its bright color and pleasant aroma in various religious ceremonies. Temples would burn it as incense to create a purifying atmosphere believed to bring divine favor and protection. The use of saffron for ancient Greeks and Romans was very vast. They prized it as a perfume or deodorizer, and scattered it about their public spaces: royal halls, courts, and amphitheaters alike.

2.4 Ayurvedic and Indian Traditions

In India, saffron was known for its value and medicinal properties, especially in Ayurveda, as a valuable and therapeutic ingredient. The aromatic properties of saffron, directly attributable to safranal, were integral to its use as a stimulant, aphrodisiac, and mood-modulating agent in Ayurvedic preparations.

2.5 Traditional Chinese Medicine

Saffron, the dried stigmas of the flowers of Crocus sativus L., is considered able to promote blood circulation and prevent blood stasis, cool and detoxify the blood, relieve depression and calm the mind. According to textual research, saffron was introduced to China during the Ming Dynasty (1368–1644 AD) and had a long history of medicinal use. According to the Compendium of Materia Medica, saffron has been mainly used to treat palpitations, promote blood circulation and relieve depression or restlessness. As a common traditional Chinese medicine (TCM), saffron was employed to treat depression and some other inflammatory diseases in ancient China due to its antioxidant, anti-inflammatory, and antidepressant properties.

2.6 Tibetan and Other Traditions

Safranal is an active component of the traditional Tibetan medicine (TTM) saffron, which has potential anticancer activity. In traditional Tibetan medicine, saffron was employed as a powerful medicinal herb, a practice consistent with the broader pan-Asian integration of saffron into healing systems.

In the Middle East, the plant has been used for centuries, alike in India and in Spain. For several millennia, saffron (Crocus sativus) has been used for medicinal purposes as a phytotherapeutic agent against different diseases. Across all these traditions, the aromatic properties of saffron—now understood to derive largely from safranal—played a central role: it was inhaled as incense, infused in beverages, added to baths, and incorporated into topical preparations.

3. Key Active Constituents and Mechanisms of Action

3.1 Safranal as a Bioactive Constituent

The main components of saffron—crocin, crocetin, picrocrocin, and safranal—are responsible for various properties ranging from its color and aroma to its medicinal effects. Safranal is specifically the dominant driver of the spice's pharmacological activity within the volatile fraction. Safranal as a monoterpene aldehyde extracted from the essential oil of saffron possesses several biological activities including antihyperglycemic, anti-inflammatory, antioxidant, anti-seizure, and anxiolytic properties.

3.2 GABAergic Mechanisms

One of the most thoroughly characterized mechanisms of safranal is its interaction with the GABAergic system. The effects of safranal on the central nervous system are not attributable to a single molecular pathway but rather to a coordinated modulation of inhibitory and excitatory neurotransmission. Safranal enhances GABAergic inhibition primarily through interaction with the benzodiazepine (BDZ) binding site of the GABA_A receptor complex. Safranal has been shown to act as a positive allosteric modulator at GABA_A receptors—that is, potentiating inhibitory GABA transmission in a similar way to benzodiazepines—contributing to anxiolytic and sedative effects, while also influencing serotonergic signaling.

Doses of 72.75, 145.5, and 291 mg per kg of body weight provided 30%, 100%, and 100% improvement in mortality rate in seizure models, respectively. This study established that this effect was mediated partly through the GABA(A)-benzodiazepine receptor complex, as the protective action was abolished when flumazenil was given.

3.3 Monoaminergic Modulation

Researchers have found that saffron components such as crocin, crocetin, and safranal mitigate depressive symptoms through neurotransmitter regulation, anti-inflammatory effects, and neuroprotection. The proposed mechanism involves inhibiting serotonin reuptake in synapses, thereby prolonging elevated levels and enhancing its positive impact on mood regulation. Crocin and safranal can inhibit the reuptake of serotonin and dopamine, allowing more of these mood-regulating neurotransmitters to remain active in the brain.

3.4 Glutamate and Excitotoxicity Modulation

Safranal reduces kainic acid–induced elevations in extracellular glutamate and aspartate, indicating suppression of excitotoxic neurotransmitter release. This dual action—enhancing inhibitory GABA signaling while simultaneously suppressing excitatory glutamate activity—helps explain the compound's broad neuroprotective and anticonvulsant profile observed in preclinical models.

3.5 Antioxidant Mechanisms

The outcomes of human and animal experiments indicate that therapeutic impacts of saffron and its constituents, crocin, crocetin, and safranal, are mainly mediated via inhibiting inflammatory reactions and scavenging free radicals. Investigation into the pharmacological properties of safranal has established its immense antioxidant potential. Safranal acts as a direct radical scavenger and upregulates endogenous antioxidant defense systems. Specifically, in animal studies, safranal increased levels of glutathione (GSH) and the activity of antioxidant enzymes including catalase (CAT) and superoxide dismutase (SOD).

3.6 Nrf2 Signaling Pathway

Saffron constituents—including crocin, crocetin, and safranal—have many pharmacological properties such as anti-oxidant, anti-inflammatory, antitumor, antigenotoxic, anti-depressant, hepatoprotective, cardioprotective, and neuroprotective. The nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway plays an important role against inflammation, oxidative stress, and carcinogenesis. The Nrf2-keap1 complex is disrupted, causing Nrf2 to accumulate in the cytoplasm with high concentrations, leading to its translocation to the nucleus and triggering several cytoprotective events such as molecular chaperones, antioxidant and phase II detoxification enzymes, and anti-inflammatory responses.

3.7 Anti-inflammatory Mechanisms

Evidence from in vitro and in vivo models, as well as clinical studies, suggests that saffron primarily exerts its beneficial effects through the modulation of oxidative stress, apoptosis, autophagy, lipid metabolism, and the regulation of key molecular pathways, including the NF-κB, PI3K/Akt/mTOR, and Nrf2/HO-1 pathways. Specifically, NF-κB downregulation by saffron constituents reduces the transcription of pro-inflammatory cytokines, a mechanism relevant to safranal's observed anti-inflammatory actions across multiple organ systems.

3.8 Anticancer Mechanisms

Safranal exhibits high antioxidant activity, along with cytotoxicity towards cancer cells in vitro. One of its anticancer mechanisms of action involves disruption of the normal assembly dynamics of cellular microtubules. Additional anticancer mechanisms include induction of apoptosis and cell cycle arrest. Safranal arrested cell cycle at G2/M phase as observed by immunoblot analyses and apoptosis using liver cancer cell lines (HepG2). This marked effect on DNA damage machinery indicated ER stress-mediated apoptosis.

3.9 Cardiovascular Mechanisms

Extensive evidence exists on safranal's antihypertensive, anti-ischemic, and relaxant effects, which are mediated through antioxidants, regulation of Ca²⁺ homeostasis, inhibition of smooth muscle cell contraction, and antiapoptotic effects in the cardiovascular system. Antihypertensive effects of safranal may be caused by blocking calcium channels and relaxing smooth muscle cells, affecting the gamma-aminobutyric acid (GABA)-benzodiazepine receptor complex, or through the diuretic activity of saffron.

4. Scientific Evidence by Area of Use

4.1 Central Nervous System: Depression and Anxiety

4.1.1 Antidepressant Effects

Safranal has been shown to have antidepressant properties in animals and pilot studies in humans. The bulk of human-level evidence, however, pertains to saffron extract preparations that contain safranal alongside crocin and other constituents, making it difficult to isolate safranal's sole contribution in clinical outcomes.

An analysis of seven randomized and placebo-controlled trials concluded that saffron was effective in the treatment of major depressive disorder (MDD) and had comparable efficacy to synthetic antidepressants. A meta-analysis of 8 studies assessing depression outcomes revealed a nonsignificant difference between saffron and SSRIs in reducing depressive symptoms (SMD = 0.10; 95% CI: −0.09 to 0.29). This result suggests statistical non-inferiority of saffron to SSRIs in mild-to-moderate depression.

A daily dose of 30 mg of saffron extract, administered over 6 weeks, was found to be as effective as the selective serotonin reuptake inhibitor citalopram in treating major depressive disorder with anxious distress. In teenagers and healthy adults, a daily dose of 28 mg of saffron extract taken for 4 or 8 weeks also reduced symptoms of anxiety and depression, improved mood, and enhanced stress management.

More extensive, well-controlled trials are required to validate the promising existing evidence and confirm the effectiveness, safety profile, and mechanism of action of saffron in the treatment of MDD. It must be noted that most published clinical trials are short in duration (4–12 weeks), relatively small in sample size, and involve whole saffron extract rather than isolated safranal—limiting the degree to which conclusions can be attributed to safranal specifically.

4.1.2 Anxiolytic Effects

Studies showed that saffron aqueous extract and safranal, but not crocins, had anxiolytic and hypnotic effects in preclinical animal models. Safranal has been shown to act as a positive allosteric modulator at GABA_A receptors, potentiating inhibitory GABA transmission in a manner similar to benzodiazepines, contributing to anxiolytic and sedative effects, while also influencing serotonergic signaling.

A 2020 randomized, double-blind, parallel-group clinical trial published in Frontiers in Nutrition examined the effects of saffron extract supplementation on mood, well-being, and response to a psychosocial stressor in healthy adults. The similar pattern of effects of saffron compared to SSRIs in clinical trials on depression was noted, and safranal may modulate heart rate variability through its action on GABAergic systems. The evidence for anxiolytic activity remains stronger in preclinical settings than in rigorously controlled human trials.

4.2 Central Nervous System: Anticonvulsant Activity

Safranal is an effective anticonvulsant in animal models, shown to act as an agonist at GABA_A receptors. It was shown that safranal could reduce seizure duration and delay the onset of tonic convulsions. Peripheral administration of safranal reduced the incidence of both generalized tonic-clonic seizures (GTCS) and minimal clonic seizures (MCS) in a dose-dependent manner. A significant increase in latency of these seizure phases was also observed.

Results of this study demonstrated that safranal could exert anticonvulsant activity in the pentylenetetrazol (PTZ) model, and this effect may be mediated, at least partly, through the GABA(A)-benzodiazepine receptor complex. Mechanistic studies demonstrated partial reversal of anticonvulsant effects by flumazenil, confirming involvement of the GABA_A-BDZ receptor complex, while opioid receptor antagonists showed minimal interference.

Evidence strength: Preclinical (animal model) data only. No controlled human trials on safranal as an anticonvulsant agent have been published as of the most recent literature reviews.

4.3 Central Nervous System: Sleep and Hypnotic Activity

Safranal-induced hypnotic effects are closely associated with alterations in sleep architecture. Experimental models reveal a significant increase in non–rapid eye movement (NREM) sleep duration and delta-wave power, accompanied by shortened sleep latency. These effects are mechanistically linked to safranal's interaction with GABA_A receptors at the benzodiazepine binding site, consistent with the general sleep-promoting properties of GABAergic agents. Clinical studies specifically isolating safranal's hypnotic effects in humans are limited.

4.4 Central Nervous System: Neuroprotection in Neurodegenerative Disease

According to a comprehensive review, most of the studies related to safranal's pharmacological effects on the CNS include antianxiety, analgesic, anticonvulsant, anti-ischemic, anti-tremor, memory enhancement and its protective effects on neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases.

Safranal could improve cognitive and memory deficits and exerts numerous neuropharmacological properties as anxiolytic, anticonvulsant, and antidepressant. Several studies have reported that safranal may be an effective treatment for various neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

In the clinical domain, saffron at 30 mg/day showed non-inferiority to donepezil (10 mg/day) and memantine (20 mg/day) in patients with mild-to-moderate and moderate-to-severe Alzheimer's disease. Trials lasting 16 to 52 weeks demonstrated significant improvements on validated cognitive scales such as the Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating – Sum of Boxes (CDR-SB), with fewer gastrointestinal side effects compared to standard treatments. Again, these results are for saffron extract as a whole, not for isolated safranal.

The preponderance of evidence regarding neuroprotective and antidepressant effects reported in animal models is largely indirect, with a paucity of quantitative in vivo studies on the brain/plasma ratio and the ability of safranal to cross the blood–brain barrier.

4.5 Anticancer Effects

Safranal is an active ingredient in saffron used in traditional medicine, and the biological activity of saffron in anti-cancer is a developing area of investigation. In vitro studies demonstrate meaningful cytotoxic selectivity. Neuroblastoma cells were cultured and exposed to safranal (0, 10, 15, 20, 50 µg/ml). Cell proliferation was examined using the MTT assay. Apoptotic cells, cell cycle distribution, and sub-G1 fraction were analyzed using flow cytometric analysis after propidium iodide staining. Safranal inhibited the growth of malignant cells in a dose- and time-dependent manner. The IC₅₀ values against the neuroblastoma cell line were determined as 11.1 and 23.3 µg/ml after 24 and 48 hours, respectively.

Anticancer activity of safranal was also seen in hepatic carcinoma cells using in vitro, in silico, and network analyses. Safranal arrested cell cycle at G2/M phase as observed by immunoblot analyses and apoptosis using liver cancer cell lines (HepG2).

In angiogenesis research, safranal inhibited the proliferation of primary human umbilical vein endothelial cells (HUVEC) with an IC₅₀ of 300 µM and blocked VEGF secretion in HepG2 cells. Furthermore, safranal inhibited VEGF-induced angiogenesis in vitro and ex vivo via scratch wound assay, tube formation assay, transmembrane assay, and aortic ring assay.

In glioblastoma research, CCK-8, GBM-brain organoid co-culture experiments, and 3D tumour spheroid invasion assays showed that safranal inhibited GBM cell proliferation and invasion in vitro. Network pharmacology, RNA-seq, molecular docking analysis, western blotting, apoptosis, and cell cycle assays predicted and verified that safranal could promote GBM cell apoptosis and G2/M phase arrest and inhibit the PI3K/AKT/mTOR axis. In vivo experiments showed that safranal could inhibit GBM cell growth alone and in combination with temozolomide (TMZ).

Evidence strength: Predominantly in vitro and limited animal (in vivo) data. A pre-clinical study demonstrated a neuroblastoma cell line to be highly sensitive to safranal-mediated growth inhibition and apoptotic cell death, although the molecular mechanisms of safranal action are not yet clearly understood. No controlled human clinical trials specifically evaluating safranal's anticancer efficacy have been published. All anticancer evidence must therefore be considered preliminary and hypothesis-generating.

4.6 Cardiovascular Effects

In animal models, chronic administration of safranal (1, 2, and 4 mg/kg/day) could reduce mean systolic blood pressure in desoxycorticosterone acetate (DOCA) salt-induced hypertensive rats, but not in normotensive animals, in which antihypertensive effects of safranal did not persist. This finding suggests a conditional, pathology-dependent antihypertensive effect rather than a generalized blood pressure–lowering action.

Evidence strength: Animal and mechanistic studies only. No controlled human trials on safranal's cardiovascular effects have been published as standalone investigations.

4.7 Respiratory and Antiasthmatic Effects

Other effects of safranal include antiasthmatic properties, documented primarily in preclinical models. Safranal in diabetic rat groups inhibited the level of malondialdehyde (MDA) and nitric oxide (NO) in bronchoalveolar lavage fluid (BALF) supernatant and lung homogenate. The median effective dose (ED₅₀) values were 0.42, 0.58, and 0.48, 0.71 mg/kg, respectively. Safranal in the diabetic groups increased the level of reduced glutathione (GSH) and the activity of catalase and superoxide dismutase in BALF supernatant and lung homogenate. These findings indicate safranal's ability to reduce pulmonary oxidative stress in a disease model context.

Evidence strength: Preclinical (animal model) only.

4.8 Metabolic Effects: Antidiabetic and Nephroprotective Activity

Protective effects of safranal on metabolic syndrome and diabetic nephropathy have been shown in preclinical models. Moreover, the protective effects of this agent on metabolic syndrome and diabetic nephropathy have been demonstrated. Antihyperglycemic activity of safranal has also been documented in animal models of diabetes, where it was shown to modulate oxidative stress pathways relevant to diabetes-related organ damage.

Evidence strength: Preclinical only; human studies on safranal for metabolic disease are absent from the published literature.

4.9 Anti-inflammatory and Hepatoprotective Activity

Investigation by various research groups has established safranal as an anti-inflammatory, antidepressant, anxiolytic, antiasthmatic, antihypertensive, anticonvulsant, anticancer, antitussive, and antigenotoxic agent. In hepatoprotective research, saffron constituents including safranal were shown to modulate the Nrf2/HO-1 pathway to protect liver cells against oxidative damage and chemical-induced inflammation in animal models. When administered to diethylnitrosamine (DEN)-treated rats, safranal significantly inhibited proliferation (assessed by Ki-67) and induced apoptosis (assessed by TUNEL and M30 CytoDeath assays).

Evidence strength: In vitro and animal models; clinical evidence in humans is lacking.

5. Body Systems Associated with Safranal

Based on the available scientific literature, safranal's documented or investigated pharmacological activity spans the following body systems:

Central Nervous System: Neuroprotective activities; anticonvulsant, anxiolytic, antidepressant, analgesic, anti-tremor, and memory-enhancing effects documented in preclinical models; pilot data in humans for antidepressant and anxiolytic actions.
Cardiovascular System: Cardioprotective activities; antihypertensive and anti-ischemic effects demonstrated in animal models.
Respiratory System: Antiasthmatic and antitussive activities; pulmonary antioxidant effects in diabetic animal models.
Renal System: Nephroprotective activities; protection against diabetic nephropathy in animal models.
Gastrointestinal System: Gastrointestinal protective activities reported in preclinical studies.
Hepatic System: Hepatoprotective effects via Nrf2 signaling pathway modulation, documented in vitro and in animal models.
Oncology (Multiple Systems): In vitro cytotoxicity demonstrated against neuroblastoma, hepatocellular carcinoma, glioblastoma, and other cancer cell lines.
Metabolic System: Antihyperglycemic and hypolipidemic effects in animal models; protective effects against metabolic syndrome.
Ocular System: Anticataract effects reported; saffron (and its constituents including safranal) has been studied in retinal neurodegeneration.

6. Dosage Forms and Dosages Reported in Studies

6.1 Clinical (Human) Studies Using Saffron Extract

Given that safranal is rarely administered as an isolated compound in human clinical trials, reported dosages pertain to standardized saffron extracts in which safranal content is a defined or measured fraction.

A daily dose of 30 mg of saffron extract, administered over 6 weeks, was found to be as effective as the SSRI citalopram in treating major depressive disorder with anxious distress.
A saffron extract termed Affron® at a low dose of 28 mg/day was assessed in clinical trials for mood, stress, anxiety, and sleep quality in healthy adults after one month of treatment.
In teenagers and healthy adults, 28 mg of saffron extract per day, taken for 4 or 8 weeks, reduced symptoms of anxiety and depression.
Saffron at 30 mg/day showed non-inferiority to donepezil (10 mg/day) and memantine (20 mg/day) in patients with mild-to-moderate and moderate-to-severe Alzheimer's disease.
At high doses (200 and 400 mg/day), saffron tablets changed some hematological and biochemical parameters in healthy adult volunteers; however, these changes were within normal ranges and were not clinically important.

6.2 Preclinical (Animal) Dosages of Safranal

Doses of 72.75, 145.5, and 291 mg/kg of body weight provided 30%, 100%, and 100% improvement in mortality rate in seizure models in preclinical studies.
Chronic administration of safranal at 1, 2, and 4 mg/kg/day reduced mean systolic blood pressure in DOCA salt-induced hypertensive rats.
For subacute toxicity assessment, safranal was administered orally to male rats once daily for 21 days.
Neuroblastoma cells were exposed to safranal at 0, 10, 15, 20, and 50 µg/ml concentrations in vitro.

7. Safety Considerations

7.1 Acute Toxicity

A dedicated study evaluated the acute and subacute toxicity of safranal as an isolated compound in rodents. According to LD₅₀ values, safranal was low-toxic in acute intraperitoneal route and practically non-toxic in acute oral administration in both mice and rats. Specific values reported were: The intraperitoneal LD₅₀ values of safranal were 1.48 mL/kg in male mice, 1.88 mL/kg in female mice, and 1.50 mL/kg in male rats. Oral LD₅₀ values were 21.42 mL/kg in male mice, 11.42 mL/kg in female mice, and 5.53 mL/kg in male rats.

This study showed safranal toxicity was poor in acute IP exposure and practically nontoxic in both mice and rats for acute oral administration. Partial variations between oral values and IP LD₅₀ can be due to first-pass metabolism and poor absorption after oral treatment.

7.2 Subacute Toxicity Findings

In subacute toxicity studies, safranal changed some hematological and biochemical parameters. Specifically: In hematological tests, a significant decrease in RBC counts, hematocrit, hemoglobin, and platelets were observed. Safranal decreased cholesterol, triglyceride, and alkaline phosphatase. Lactate dehydrogenase and serum urea nitrogen were increased by safranal. Regarding organ histology, histological studies indicated that safranal did not have any toxic effect on the heart, liver, and spleen. However, pathological changes were seen in the kidney and lung in the subacute exposure protocol.

7.3 Saffron Co-administration and Toxicity Mitigation

Research has shown an interesting interaction between safranal and the broader saffron extract. A study published in PMC examined whether co-administration of whole saffron aqueous extract could modify safranal's acute toxicity in rats. Rats received safranal (1.2 mL/kg, IP) plus saffron aqueous extract (25–100 mg/kg, IP). One and four days after treatments, the percentages of mortality were assessed. Results suggested that other saffron constituents may modulate safranal's toxicity, highlighting the complexity of whole-extract versus isolated compound pharmacology.

7.4 Saffron at Therapeutic Doses in Humans

In humans, saffron with doses between 1.2 and 2 g induced nausea, vomiting, diarrhea, and bleeding. These effects were reported at supra-therapeutic doses well beyond typical supplemental intake. At doses used in clinical trials (28–30 mg/day of standardized extract), saffron has demonstrated a favorable safety profile in multiple randomized controlled trials.

7.5 Pregnancy and Lactation Considerations

Another great concern has been the effect of saffron administration on pregnant women and their neonates. To evaluate lactating toxicity in mice, saffron was administered orally to mothers once daily for 21 days, after delivery, during the lactating period at doses of 500, 1000, and 2000 mg/kg body weight, and its administration did not have any toxic effect on liver. However, histopathology changes were noticed in the kidney of neonates, but the doses administered were quite high. These findings were obtained at high experimental doses far exceeding typical human consumption.

7.6 Bioavailability Limitations

A critical pharmacological limitation is that safranal's poor oral bioavailability is a major limitation. The aldehyde group of safranal renders it chemically reactive and susceptible to rapid metabolism. Further studies are needed to determine the stable and orally absorbable form of safranal, derivatizing its aldehyde group without compromising its potency. This bioavailability constraint means that even when promising activities are demonstrated in in vitro systems, translating those concentrations to systemic in vivo levels via oral administration remains challenging.

7.7 Potential Drug Interactions

Given safranal's confirmed action as a GABA_A receptor positive allosteric modulator, concurrent use with other CNS depressants—including benzodiazepines, barbiturates, alcohol, and sedative-hypnotic drugs—carries a theoretical risk of additive CNS depression. Its serotonergic reuptake inhibitory properties similarly raise a theoretical concern for pharmacodynamic interactions with serotonergic medications. Clinical studies have shown that saffron extracts can perform comparably to standard antidepressants in mild-to-moderate depression, but the safety of combination with pharmacological antidepressants has not been studied specifically for isolated safranal. The broader evidence base for saffron extracts and their effect on calcium channels (relevant to the antihypertensive mechanism) suggests the need for caution in individuals taking calcium channel blocking medications.

7.8 Overall Evidence Gaps

Based on the documents, safranal is considered a promising therapeutic agent, although more clinical studies are needed to verify the beneficial effects of safranal in humans. A major limitation in saffron research is the insufficient characterization of the extracts used; most studies lack standardization of individual constituent content, making it impossible to attribute observed effects to safranal specifically versus other co-occurring bioactives. Furthermore, the lipophilic and volatile nature of safranal creates substantial challenges for pharmaceutical development, including formulation stability and bioavailability optimization.

References

Health Conditions

Health conditions that Safranal may help support.

Sleep QualityScientific
Safranal is a principal volatile constituent of saffron (Crocus sativus) responsible for its characteristic aroma and a key pharmacological mediator of saffron's sleep-promoting and anxiolytic effects. It acts as a GABA-A receptor agonist and inhibits serotonin reuptake. Animal studies confirm hypnotic properties, and safranal-containing saffron extracts have demonstrated sleep improvement in human RCTs. Safranal is part of the active phytochemical basis for saffron's clinical sleep evidence.

Body Systems

Body systems that Safranal may help support.

No body systems available.